Evenity® (generic name: romosozumab-aqqg) is an injected medication to slow down osteoporosis in women after menopause. It is prescribed for patients at high risk of bone fractures, who cannot use another osteoporosis treatment, or for whom other osteoporosis medicines did not work well.
Evenity supplies a humanized monoclonal antibody (romosozumab) that targets sclerostin. This molecule inhibits new bone-cell formation and stimulates bone-cell destruction. By blocking sclerostin, romosozumab has the dual effect of increasing bone formation and decreasing bone resorption. Like skin and hair, bones are living organs that constantly renew their cells. The changes brought on by menopause reduce bone density, which increases the risk that fractures can occur more frequently in the vertebrae (spine), carpals, hips, pelvis and upper arms.
Dosage
Evenity is treatment option administered as a subcutaneous injection by your healthcare provider. The standard dosage is two injections monthly for six months – 12 doses. Taking calcium and vitamin D supplements is necessary while you receive these doses.
If you miss a dose of Evenity, contact your healthcare provider immediately to schedule your next dose as soon as possible. The next dose should be scheduled every month from the date of the last injection.
Reviews
There are no reviews yet.